Prolia, Osteoporosis Therapies Improve Bone Health in Prostate Cancer Patients, Review Suggests

Prolia, Osteoporosis Therapies Improve Bone Health in Prostate Cancer Patients, Review Suggests
A review of clinical trial results revealed that patients with non-metastatic prostate cancer receiving androgen deprivation therapy (ADT) can benefit from osteoporosis therapies, known as bisphosphonates, and from Prolia (denosumab), which significantly increase bone mineral density (BMD). The review, “Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer,” was published in the journal Annals of Internal Medicine
Subscribe or to access all post and page content.